Barclays PLC Kezar Life Sciences, Inc. Transaction History

Barclays PLC

  • $377 Billion
  • Q3 2024

A detailed history of Barclays PLC transactions in Kezar Life Sciences, Inc. stock. As of the latest transaction made, Barclays PLC holds 1 shares of KZR stock, worth $7. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1
Previous 218 99.54%
Holding current value
$7
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024
SELL
$0.53 - $0.77 $115 - $167
-217 Reduced 99.54%
1 $0
Q2 2024

Aug 14, 2024
SELL
$0.6 - $0.92 $29,940 - $45,908
-49,900 Reduced 99.57%
218 $0
Q1 2024

May 15, 2024
SELL
$0.8 - $1.05 $38,335 - $50,314
-47,919 Reduced 48.88%
50,118 $45,000
Q4 2023

Feb 15, 2024
BUY
$0.72 - $1.15 $61,520 - $98,261
85,445 Added 678.57%
98,037 $93,000
Q3 2023

Nov 07, 2023
SELL
$1.08 - $2.54 $1,763 - $4,147
-1,633 Reduced 11.48%
12,592 $15,000
Q2 2023

Aug 03, 2023
SELL
$2.31 - $3.06 $1.88 Million - $2.49 Million
-814,809 Reduced 98.28%
14,225 $35,000
Q1 2023

May 04, 2023
BUY
$3.13 - $7.31 $2.01 Million - $4.69 Million
641,543 Added 342.17%
829,034 $2.59 Million
Q4 2022

Feb 13, 2023
BUY
$6.39 - $8.8 $219,030 - $301,637
34,277 Added 22.37%
187,491 $1.32 Million
Q3 2022

Nov 03, 2022
BUY
$7.99 - $10.75 $1.19 Million - $1.6 Million
149,189 Added 3706.56%
153,214 $1.32 Million
Q2 2022

Aug 12, 2022
SELL
$4.58 - $17.13 $9,727 - $36,384
-2,124 Reduced 34.54%
4,025 $33,000
Q1 2022

May 16, 2022
SELL
$12.3 - $18.33 $446,649 - $665,617
-36,313 Reduced 85.52%
6,149 $102,000
Q4 2021

Feb 14, 2022
BUY
$7.44 - $16.72 $77,844 - $174,941
10,463 Added 32.7%
42,462 $710,000
Q3 2021

Nov 09, 2021
BUY
$4.85 - $9.73 $46,627 - $93,544
9,614 Added 42.95%
31,999 $277,000
Q2 2021

Aug 13, 2021
SELL
$4.93 - $6.46 $108,410 - $142,055
-21,990 Reduced 49.55%
22,385 $122,000
Q1 2021

May 13, 2021
BUY
$5.24 - $6.99 $84,180 - $112,294
16,065 Added 56.75%
44,375 $264,000
Q4 2020

Feb 11, 2021
SELL
$4.77 - $6.58 $18,154 - $25,043
-3,806 Reduced 11.85%
28,310 $148,000
Q3 2020

Nov 12, 2020
SELL
$4.36 - $5.5 $7,856 - $9,911
-1,802 Reduced 5.31%
32,116 $155,000
Q2 2020

Aug 12, 2020
BUY
$3.6 - $7.75 $20,203 - $43,493
5,612 Added 19.83%
33,918 $175,000
Q1 2020

May 13, 2020
SELL
$2.77 - $5.75 $15,254 - $31,665
-5,507 Reduced 16.29%
28,306 $124,000
Q4 2019

Feb 10, 2020
BUY
$2.5 - $4.26 $19,685 - $33,543
7,874 Added 30.36%
33,813 $135,000
Q3 2019

Nov 14, 2019
BUY
$3.0 - $7.58 $2,706 - $6,837
902 Added 3.6%
25,939 $85,000
Q2 2019

Aug 14, 2019
BUY
$7.09 - $21.9 $152,286 - $470,390
21,479 Added 603.68%
25,037 $193,000
Q1 2019

May 15, 2019
BUY
$16.83 - $23.75 $59,881 - $84,502
3,558 New
3,558 $63,000
Q4 2018

Feb 14, 2019
SELL
$20.21 - $32.9 $38,944 - $63,398
-1,927 Closed
0 $0
Q3 2018

Nov 14, 2018
BUY
$15.5 - $21.41 $29,868 - $41,257
1,927 New
1,927 $41,000

Others Institutions Holding KZR

# of Institutions
62
Shares Held
38.4M
Call Options Held
13.8K
Put Options Held
600
View Full List

About Kezar Life Sciences, Inc.

KZR Quotes by TradingView
  • Ticker KZR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,369,504
  • Market Cap $510M
  • Description
  • Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...
More about KZR
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email